argenx SE (NASDAQ:ARGX – Get Rating) – Equities research analysts at Jefferies Financial Group cut their FY2025 earnings per share (EPS) estimates for argenx in a research report issued to clients and investors on Wednesday, January 25th. Jefferies Financial Group analyst A. Tewari now forecasts that the company will post earnings per share of $0.11 for the year, down from their previous estimate of $0.18. The consensus estimate for argenx's current full-year earnings is ($15.59) per share. Jefferies Financial Group also issued estimates for argenx's FY2026 earnings at $11.08 EPS and FY2027 earnings at $19.83 EPS.
Get argenx alerts:argenx (NASDAQ:ARGX – Get Rating) last announced its quarterly earnings results on Thursday, October 27th. The company reported ($4.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.50) by ($0.76). The company had revenue of $146.49 million during the quarter, compared to analyst estimates of $115.49 million. argenx had a negative net margin of 295.08% and a negative return on equity of 66.04%.
A number of other analysts have also recently weighed in on the company. HC Wainwright increased their price objective on argenx from $440.00 to $480.00 and gave the stock a "buy" rating in a research report on Tuesday, January 10th. Morgan Stanley increased their target price on shares of argenx from $401.00 to $450.00 and gave the company an "overweight" rating in a research note on Friday, October 28th. Truist Financial increased their price target on shares of argenx from $410.00 to $420.00 and gave the stock a "buy" rating in a research report on Friday, October 28th. Barclays raised their price objective on shares of argenx from €405.00 ($440.22) to €450.00 ($489.13) and gave the stock an "overweight" rating in a report on Tuesday, December 6th. Finally, Wells Fargo & Company raised their price target on shares of argenx from $461.00 to $469.00 and gave the company an "overweight" rating in a report on Tuesday, October 18th. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $453.23.argenx Stock Down 0.3 %
Shares of argenx stock opened at $380.90 on Friday. The business's fifty day simple moving average is $384.06 and its 200-day simple moving average is $374.45. argenx has a 52 week low of $249.50 and a 52 week high of $407.93. The firm has a market cap of $21.07 billion, a PE ratio of -22.16 and a beta of 0.80.
Institutional Trading of argenx
A number of large investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC increased its stake in shares of argenx by 51.9% in the second quarter. Jennison Associates LLC now owns 1,545,227 shares of the company's stock worth $585,456,000 after purchasing an additional 527,812 shares in the last quarter. FMR LLC lifted its position in argenx by 6.3% during the second quarter. FMR LLC now owns 4,974,343 shares of the company's stock valued at $1,884,680,000 after purchasing an additional 294,228 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in argenx by 3.0% during the second quarter. Price T Rowe Associates Inc. MD now owns 6,377,316 shares of the company's stock valued at $2,416,237,000 after purchasing an additional 182,835 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in argenx by 62.7% during the first quarter. Goldman Sachs Group Inc. now owns 334,169 shares of the company's stock valued at $105,366,000 after purchasing an additional 128,759 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of argenx by 1,043.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 135,219 shares of the company's stock worth $51,225,000 after acquiring an additional 123,392 shares in the last quarter. Hedge funds and other institutional investors own 57.29% of the company's stock.
About argenx
(Get Rating)
argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.
Recommended Stories
- Get a free copy of the StockNews.com research report on argenx (ARGX)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.